Available online www.ijpras.com

International Journal of Pharmaceutical Research & Allied Sciences, 2026, 15(2):104-113
https://doi.org/10.51847/2bOEalyk9r

Original Article

ISSN : 2277-3657
CODEN(USA) : IJPRPM

Cell-Free Pharmaceutical Biotechnology as a Modular Manufacturing Architecture for Rapid, Distributed, and Reconfigurable Therapeutic Production across Therapeutic Modalities

Hassan Ali[1]*, Mariam Farooq[1], Usman Shah[2], Bilal Khan[3], Sana Malik[4]

[1]Department of Cell-Free Biotechnology and Modular Manufacturing, Faculty of Pharmacy, University of Agriculture Faisalabad, Faisalabad, Pakistan.
[2]Department of Rapid and Distributed Production, Faculty of Pharmacy, National University of Sciences and Technology, Islamabad, Pakistan.
[3]Department of Reconfigurable Therapeutic Production, Faculty of Pharmacy, University of Punjab, Lahore, Pakistan.
[4]Department of Therapeutic Modalities and Architecture, Faculty of Pharmacy, University of Karachi, Karachi, Pakistan.

***Email:** hassan.ali@uaf.edu.pk*

ABSTRACT

Cell-dependent biomanufacturing has enabled diverse therapeutic products, yet its reliance on living production hosts can constrain rapid process reconfiguration, local production, and transfer across therapeutic modalities. Cell-free pharmaceutical biotechnology removes the requirement to maintain an intact production cell, but current evidence remains fragmented across reaction engineering, template design, post-translational processing, purification, stabilization, and distributed implementation. This Original Platform-Design Theory Article proposes a modular manufacturing architecture that connects a reusable cell-free production kernel with product-specific template, maturation, purification, formulation, quality, and qualification modules. The architecture distinguishes reusable infrastructure from elements that must be re-established for each product, modality, scale, or manufacturing site. Reaction-system resources are treated as interacting biochemical determinants rather than independently replaceable ingredients, while therapeutic templates are linked to folding, modification, conversion, impurity, and critical-quality-attribute requirements. Quality control is positioned as a continuous evidence layer incorporating material provenance, contamination control, recipe versioning, lot variation, analytical transfer, and intersite reproducibility. Scale transition and economic feasibility are separated from bench-scale expression because changes in extract preparation, mass transfer, resource consumption, downstream recovery, quality-system burden, and local infrastructure may alter platform performance. Proposed readiness criteria progress from conceptual specification and component functionality to integrated reproducibility, cross-lot and cross-site transfer, scale feasibility, and product-specific translational evidence. The original contribution is a conditional architecture for determining when modular substitution may be plausible and when requalification is required. It is not a validated manufacturing standard, predictive model, regulatory pathway, clinical recommendation, or deployment-ready system. Its utility requires prospective testing across therapeutic modalities, production configurations, sites, scales, and intended-use conditions.

Key words: *Pharmaceutical biotechnology, Biomanufacturing, Cell factory, Bioprocess, Biologic developability, Synthetic biology*

Received: 04 March 2026; **Revised:** 06 June 2026; **Accepted:** 12 June 2026

INTRODUCTION

Cell-free biotechnology relocates transcription, translation, and associated biochemical functions from an intact cell into an accessible reaction environment. This separation can permit direct manipulation of reaction

composition, template concentration, energy systems, cofactors, and processing conditions that would otherwise be constrained by cellular viability and regulation [1]. The resulting openness creates manufacturing possibilities, but it also transfers responsibility for maintaining biochemical function from the cell to the engineered process.

The expanding application repertoire of cell-free expression includes rapid prototyping, pathway construction, protein production, biosensing, therapeutic development, and distributed synthesis. These uses demonstrate technological versatility but do not establish that the same reaction architecture, control strategy, or evidence package is suitable for every pharmaceutical product [2]. Pharmaceutical relevance depends not only on expression but also on developability, structural integrity, biological function, impurity control, stability, and intended use.

Cell-free workflows likewise remain sensitive to extract preparation, resource composition, template design, reaction conditions, analytical procedures, and operator practices. Methodological standardization is therefore necessary for interpretable comparison and reproducibility, particularly when results are transferred between laboratories or manufacturing contexts [3]. A platform claim must consequently specify which components are reusable, which are product-dependent, and which changes require renewed experimental qualification.

This article develops an original, non-empirical platform-design theory for cell-free pharmaceutical biotechnology. It proposes a modular architecture connecting reaction resources, therapeutic templates, specialized maturation functions, purification, formulation, quality control, and distributed qualification. The contribution organizes established component capabilities into proposed interface rules, readiness criteria, and decision boundaries. It does not claim exhaustive coverage, empirical validation, regulatory endorsement, universal applicability, or superiority over established cell-dependent manufacturing.

Limitations of cell-dependent pharmaceutical manufacturing

Cell-dependent pharmaceutical manufacturing couples product formation to cell growth, viability, metabolism, stress responses, genetic stability, and culture history. Compact or on-demand production therefore cannot be achieved merely by reducing bioreactor size or shortening cultivation. Demonstrations of portable biopharmaceutical manufacturing show that expression must remain integrated with process monitoring, downstream recovery, formulation, and analytical control [4]. Manufacturing agility is thus a property of the complete production system rather than of the expression host alone.

Living cell factories may also change during development or extended operation. In Chinese hamster ovary systems, genetic and phenotypic instability can affect productivity, growth, and product-related attributes, although the extent and consequence depend on the cell line, culture process, selection history, and measurement strategy [5]. Such instability does not make cell-based production intrinsically unreliable, but it creates an additional biological state that must be controlled and interpreted.

Continuous biopharmaceutical manufacturing can reduce interruptions and connect upstream and downstream operations, yet continuity does not eliminate process complexity. Stable performance requires coordinated material flow, residence-time understanding, monitoring, control, purification, and quality assessment across linked operations [6]. Continuous cell-dependent production therefore addresses some temporal inefficiencies while retaining dependencies on viable cells and integrated process control.

These limitations define the design problem rather than proving that cell-free production is categorically preferable. Living hosts may remain advantageous for products requiring complex endogenous processing, established large-scale infrastructure, or mature regulatory experience. A credible alternative must show that removing the cell does not merely exchange biological uncertainty for uncontrolled reagent variability, difficult purification, limited productivity, or an incomplete quality-evidence package.

Proposed modular cell-free manufacturing architecture

The proposed architecture begins with a product-definition package specifying therapeutic sequence, intended use, developability constraints, and product-specific critical quality attributes. This package connects to a reusable production kernel containing the extract or reconstituted translation machinery, energy-regeneration system, substrates, cofactors, salts, and controlled reaction environment. Integrated point-of-care production has shown that therapeutic synthesis can be connected with purification and quality operations, providing an empirical precedent for treating cell-free manufacture as a coordinated system rather than an isolated expression reaction [7].

Around the kernel, the architecture places capability modules that are added only when demanded by the product. Cell-free construction of protein glycosylation pathways demonstrates that specialized biosynthetic machinery

can be assembled as a distinct functional capability rather than being inseparable from a living host [8]. In the proposed theory, comparable modules may provide folding assistance, redox control, noncanonical amino-acid incorporation, membrane-associated activity, glycosylation, cleavage, or enzymatic conversion.

On-demand conjugate-vaccine production further shows that protein synthesis and glycan assembly can be integrated within a product-oriented cell-free workflow [9]. However, such evidence remains modality-specific. A module that functions for one antigen, glycan structure, or reaction configuration cannot automatically be transferred to another product without examining compatibility, impurities, recovery, stability, and relevant quality attributes.

Taken together, integrated synthesis–purification, modular glycosylation, and on-demand vaccine production show that cell-free manufacturing capabilities can be recombined, but do not establish a universally interchangeable platform [7-9]. The proposed architecture therefore defines each module through an input–output contract: intended biochemical function, controlled inputs, measurable output state, dependencies, failure modes, and product-quality implications. A substitution is modular only when these properties remain within a prospectively defined qualification envelope.

A control and evidence layer spans the complete architecture. It records template provenance, recipe version, extract and reagent lots, equipment, scale, site, operator, in-process observations, analytical results, deviations, and uncertainty. A proposed cell-free world model may organize these relationships and constrain reconfiguration hypotheses, but model output cannot be equated with pharmaceutical consequence. Product-specific evidence remains necessary whenever a change may alter identity, purity, potency, impurities, stability, or intended clinical function.

Reaction-system modules and resource composition

The reaction system is not a neutral container for a therapeutic template. Its supplements support transcription, translation, energy regeneration, redox balance, substrate availability, ionic conditions, and enzyme activity. Historical and biochemical analyses of cell-free supplement mixtures show that additives serve interacting functions and that their effects depend on the broader extract and reaction context [10]. Resource composition should therefore be treated as a coupled module rather than a collection of independently replaceable ingredients.

The source extract constitutes another controlled module because its preparation determines which ribosomes, enzymes, metabolites, membrane structures, inhibitors, and degradation activities remain active. Integrated omics analyses indicate that extract-processing methods alter the molecular state of the resulting reaction system [11]. Accordingly, two extracts described by the same host species or nominal protocol may not be functionally equivalent.

Multivariate formulation design can identify lower-cost or more reproducible combinations of reaction components, but an optimized formulation remains conditional on the tested extract, template, product, operating range, and response definition [12]. The architecture therefore requires a reaction-resource specification containing material identity, acceptable variability, preparation history, storage conditions, concentration ranges, known interactions, and the product attributes that each resource may influence.

Process robustness should be evaluated by controlled perturbation rather than by maximum expression under one preferred condition. Relevant tests include independent reagent and extract lots, preparation days, operators, reaction scales, template concentrations, and environmental conditions. A resource substitution should be accepted only when the resulting process and product remain within a product-specific evidence envelope. This rule is proposed and requires empirical validation; it is not a universal recipe, validated threshold, or regulatory comparability standard.

Template design and therapeutic-product classes

Template design determines more than whether a sequence can be expressed. Regulatory elements, transcript structure, codon selection, precursor format, and noncanonical amino-acid requirements influence the resources and processing functions needed. Genomically recoded cell-free systems permit multisite incorporation of noncanonical amino acids [13], expanding accessible product chemistry without establishing therapeutic developability.

Glycoprotein production illustrates why template exchange cannot be separated from maturation architecture. Single-pot systems can combine transcription–translation with glycosylation machinery, but performance depends on compatibility among the substrate, glycan pathway, membrane-associated components, and reaction conditions

[14]. Template portability should therefore decline as post-translational complexity increases unless the corresponding capability modules are co-qualified.

Antibodies introduce additional folding, assembly, redox, and functional requirements. Cell-free systems based on Chinese hamster ovary lysates can produce functional antibodies under defined conditions [15]. Nevertheless, successful expression or binding in one configuration cannot be generalized to other antibody formats, critical quality attributes, production scales, or intended uses.

The proposed architecture classifies products by manufacturing burden as well as conventional therapeutic modality. Relevant dimensions include folding complexity, modification dependence, membrane requirements, cleavage or conversion needs, impurity sensitivity, and formulation sensitivity. This proposed classification determines which modules may be reused and which require product-specific evidence; it is not a validated developability taxonomy.

Modular purification and formulation interfaces

Purification begins from the molecular state generated upstream. Cell-free peptide-hormone production has integrated synthesis, affinity capture, and enzymatic cleavage [16], supporting co-design between reaction and recovery modules. However, recovery or detectable biological activity alone does not establish pharmaceutical purity, stability, safety, or suitability for intended use.

Insulin manufacturing provides a related example in which precursor capture and conversion are combined through an on-column process [17]. The approach shows that tags, cleavage sites, folding state, and chromatographic conditions may be coordinated, but it does not establish a universally transferable purification sequence.

Formulation determines whether reaction materials and products tolerate storage, transport, reconstitution, and use. A thermostable, low-cost cell-free system has supported on-demand conjugate-vaccine production under specified conditions [18]. Such evidence supports formulation as an architectural module while remaining product-, reagent-, assay-, and condition-specific.

The proposed interfaces specify input state, target product state, impurity burden, recovery mechanism, excipient compatibility, stability requirements, and analytical evidence. Requalification is required when an upstream change may alter these determinants. Analytical recovery, apparent stability, or integrated processing must not be interpreted as clinical equivalence or regulatory acceptance.

Table 1 organizes the evidence, constructs, relationships, uncertainties, and boundary conditions required for definitions, components, relationships, and intended uses in cell-free pharmaceutical biotechnology as a modular manufacturing architecture for..

Table 1. Definitions, components, relationships, and intended uses in Cell-Free Pharmaceutical Biotechnology as a Modular Manufacturing Architecture for.

Component or scientific dimension	Problem addressed	Inputs or determinants	Proposed mechanism or relationship	Expected contribution	Evidence required	Failure or uncertainty risk	Boundary statement
Product-definition package — proposed	Generic platform claims neglect product needs	Sequence, intended use, developability, critical quality attributes	Product requirements determine modules and qualification depth	Product-specific configuration	Analytical, functional, stability, and use-context evidence	Incomplete attribute definition	A template is not a finished therapeutic
Production kernel — evidence-supported capability; proposed role	Reaction resources are often treated separately	Extract or purified machinery, substrates, cofactors, environment	Coupled resources establish the production state	Reusable infrastructure for compatible products	Lot and perturbation studies [10]	Hidden interactions and extract variation	Kernel reuse does not prove product equivalence
Template–modality contract — proposed	Portability varies with product burden	Sequence, precursor, folding and modification needs	Template design determines supporting capabilities	Explicit modality dependencies	Structure, activity, impurity, and stability evidence [13]	Incomplete expression or maturation	Expression does not establish therapeutic function

Maturation modules — evidence-supported capability; proposed interchange rule	Complex products need additional functions	Chaperones, redox systems, vesicles, enzymes	Optional functions are co-qualified with the product	Broader therapeutic-product range	Modification and functional characterization [14]	Incompatible machinery or heterogeneous products	A functioning module is not universally transferable
Purification interface — evidence-supported capability; proposed contract	Reaction mixtures contain diverse impurities	Product state, capture chemistry, cleavage and polishing needs	Recovery is co-designed with upstream processing	Controlled product isolation	Identity, purity, potency, and impurity evidence [16]	Loss, incomplete cleavage, co-purification	Capture is not equivalent to release
Formulation interface — evidence-supported capability; proposed contract	Portability requires storage and reconstitution control	Buffer, excipients, drying, container and temperature	Formulation preserves defined material attributes	Transport and point-of-need compatibility	Stability-indicating evidence [18]	Aggregation, degradation or variable reconstitution	Stability is product- and condition-specific
Evidence layer — proposed	Results may lack process provenance	Recipes, lots, operators, equipment and methods	Evidence accompanies every process transition	Traceability and deviation assessment	Repeated and independently reproduced measurements [3]	Missing metadata or incompatible assays	Traceability does not establish equivalence
Distributed qualification envelope — proposed	Portable execution may be mistaken for equivalent manufacture	Controlled recipe, site capability, training and analytics	Central qualification constrains local execution	Conditional multisite production	Product-specific cross-site evidence	Site drift and supply variation	Distributed feasibility is not deployment readiness

Rapid reconfiguration and distributed production

Rapid reconfiguration should mean controlled substitution of a defined template or module, not unrestricted alteration of a recipe. On-chip systems show that cell-free synthesis and purification can be integrated within compact hardware [19]. Physical integration may reduce equipment and transport requirements but does not remove material, process, recovery, or analytical controls.

Distributed production additionally requires reproducible transfer between locations. International multisite implementation demonstrates that cell-free workflows can operate across geographically separated settings when materials, procedures, training, and measurements are coordinated [20]. Successful execution nevertheless does not establish pharmaceutical equivalence, local release suitability, or regulatory authorization.

Distributed production is therefore conditional on a qualified chain linking product-specific recovery, integrated local hardware, and cross-site reproducibility rather than on portability alone [16, 19, 20]. The proposed architecture separates central design and qualification from local execution, while returning performance evidence and deviations for reassessment.

Reconfiguration distance is proposed as the number and criticality of altered interfaces. A template-only change within a characterized product class may require less requalification than changes to extract preparation, maturation, purification, formulation, scale, or site. The actual evidence burden must follow the possible consequence for product quality and intended use.

Quality control, contamination, and reproducibility

Quality control must characterize both the product and the production state. Interlaboratory studies demonstrate variability in cell-free protein synthesis despite shared materials and protocols [21]. Reproducibility therefore depends on reagent and extract lots, preparation practices, equipment, operators, environmental conditions, and analytical methods rather than on the written recipe alone.

Reaction components can alter kinetics and robustness through interacting effects [22]. Control strategies should therefore examine perturbations, response surfaces, time-dependent behavior, and failure modes instead of relying solely on endpoint expression. High output under a preferred condition cannot establish process robustness.

Contamination control must address microbial ingress, nucleic acids, endotoxin where applicable, host-derived proteins, residual enzymes, aggregates, degradation products, and downstream materials. The proposed evidence layer links these risks to material provenance and process history. Required controls remain dependent on the system, modality, route, and intended use.

Standardization may reduce uncontrolled variation but cannot eliminate biochemical, material, and analytical uncertainty. Comparability requires validated methods and product-specific criteria. Analytical similarity must remain distinct from therapeutic equivalence, while failure to detect contamination must remain distinct from comprehensive impurity control.

Table 2 organizes the evidence, constructs, relationships, uncertainties, and boundary conditions required for testable propositions, evidence requirements, and validation criteria for cell-free pharmaceutical biotechnology as a modular manufacturing architecture for.

Table 2. Testable propositions, evidence requirements, and validation criteria for Cell-Free Pharmaceutical Biotechnology as a Modular Manufacturing Architecture for.

Architecture layer or process stage	Core function	Information or material flow	Interaction with other components	Validation criterion	Potential failure mode	Human or experimental responsibility	Readiness boundary
Product definition — proposed	Translate intended use into requirements	Sequence and quality requirements enter the architecture	Determines all required modules	Complete, testable specification	Missing quality attributes	Multidisciplinary review	Definition is not validation
Reaction kernel	Generate the initial product state	Resources enter; product and impurities exit	Supplies downstream interfaces	Independent-lot reproducibility [22]	Inhibition, degradation or lot variation	Controlled perturbation studies	Function is not integrated readiness
Maturation modules	Establish folding, modification or conversion	Immature product becomes a processed product	Depends on template and reaction chemistry	Product-specific structural and functional confirmation [14]	Incomplete or heterogeneous maturation	Mechanistic experimentation	Modification is not clinical equivalence
Purification and formulation	Isolate and stabilize the product	Reaction output becomes formulated material	Coupled to upstream state and intended use	Identity, purity, potency and stability [17]	Product loss, impurities or instability	Process and analytical teams	Formulated material is not automatically releasable
Provenance layer — proposed	Preserve traceability	Lots, recipes, methods and deviations accompany results	Spans every layer	Reproducible analytical transfer [21]	Missing metadata or incompatible methods	Quality oversight and experimental confirmation	Documentation is not comparability
Distributed nodes — proposed	Execute qualified configurations locally	Instructions move outward; evidence returns	Depend on central qualification and local capability	Product-specific cross-site confirmation [20]	Site drift or supply substitution	Local execution with central assessment	Multisite operation is not authorization
Scale-transition gate — proposed	Test changed physical and operational conditions	Bench evidence informs larger-scale experiments	Affects reaction, recovery and cost	Prospective scale-transition testing	Heterogeneity or recovery loss	Engineering experiments	Bench success is not manufacturing readiness
World-model layer — proposed	Organize hypotheses and uncertainty	Evidence informs predictions;	Supports but does not replace	Held-out recipe, lot, scale and site testing	Domain shift or false confidence	Human authorization and interpretation	Model output is not

experiments test them	empirical work	pharmaceutical consequence

Scale transition and economic constraints

Scale transition changes the physical and operational context of production. Extract-preparation research shows that disruption, clarification, processing time, and related operations require reconsideration as volume increases [23]. A scalable extract process remains only one element of scalable therapeutic manufacture.

Low-cost access strategies can simplify local reagent preparation, sourcing, drying, and equipment requirements [24]. Their value lies in broadening manufacturing options, not in proving favorable pharmaceutical economics. Simplification may also alter reproducibility, contamination risk, analytical burden, and supply reliability.

Economic analysis must extend beyond reaction-reagent cost to template preparation, extract manufacture, purification, formulation, quality control, failures, waste, training, equipment, maintenance, storage, and site oversight. Distributed production may reduce transport or inventory burdens while duplicating analytical and quality-system requirements.

The architecture therefore separates scale-up, scale-out, and economic readiness. Scale-up enlarges a process, scale-out replicates qualified nodes, and economic readiness concerns sustainability for an intended use. Bench-scale expression or inexpensive formulations cannot establish these outcomes without integrated evidence.

Validation and platform-readiness criteria

Validation should test the architecture's proposed relationships rather than merely demonstrate expression. Active learning can guide exploration of multivariate cell-free production spaces and prioritize informative experiments [25]. It cannot replace mechanistic interpretation, product characterization, or independent confirmation.

AI-guided droplet screening can expand the conditions examined during reaction optimization [26]. Its findings remain bounded by selected inputs, outputs, assay fidelity, and training domain. Microscale productivity may not transfer across products, extracts, equipment, scales, or purification processes.

Platform-readiness assessment must combine interlaboratory reproducibility evidence with prospective design-space optimization and held-out validation across recipes, lots, and sites [21, 25, 26]. A proposed world model should preserve provenance, report uncertainty, and be challenged with experiments designed to reveal domain shift and failed interface assumptions.

Six proposed readiness gates organize this evidence: R0, coherent architecture and product definition; R1, component functionality; R2, integrated bench reproducibility; R3, cross-lot and cross-site transfer; R4, scale and economic feasibility; and R5, product-specific translational evidence. They are qualitative categories, not numerical scores, regulatory classifications, or approval stages.

Figure 1 presents the original conceptual synthesis for modular cell-free architecture for reconfigurable therapeutic production, showing how the article's principal components, evidence relationships, uncertainties, and decision boundaries are connected.



Figure 1. Modular Cell-Free Architecture for Reconfigurable Therapeutic Production

The figure is an original conceptual synthesis developed for "Cell-Free Pharmaceutical Biotechnology as a Modular Manufacturing Architecture for Rapid, Distributed, and Reconfigurable Therapeutic Production across Therapeutic Modalities." Arrows and grouping indicate proposed or evidence-supported relationships rather than measured effect sizes. The figure does not represent a validated predictive model, clinical recommendation, regulatory determination, or deployment-ready system.

Limitations and research priorities

Membrane-dependent functions remain a major boundary because extract-derived vesicles affect glycosylation machinery. Characterizing and enriching native membrane vesicles can improve cell-free glycoprotein synthesis [27]. This finding supports targeted engineering while showing that nominally similar extracts may contain different functional structures.

Autonomous regeneration represents another frontier. Cell-free biogenesis of all proteins required for the *Escherichia coli* translation machinery has been demonstrated under specialized conditions [28]. This does not establish autonomous therapeutic manufacture because ribosome assembly, energy supply, template maintenance, purification, quality control, and product-specific evidence remain unresolved.

Priority studies should test interface preservation through prospective module substitutions, independent lots, multiple sites, and scale transitions. Cross-modality studies should determine whether manufacturing-burden classes predict transferability better than conventional product labels. World models should be evaluated on held-out products and failed conditions rather than only within optimized datasets.

The architecture also requires evaluation in realistic quality systems, supply chains, environmental conditions, and intended-use settings. Comparative studies should examine cell-free, cell-dependent, and hybrid routes without presuming a universal solution. The theory should be revised if its interface contracts, classifications, or readiness gates fail to organize observed evidence.

CONCLUSION

Cell-free pharmaceutical biotechnology may support rapid, distributed, and reconfigurable therapeutic production only when expression is embedded within a controlled manufacturing architecture. The proposed theory separates a reusable production kernel from product-specific template, maturation, purification, formulation, quality, scale,

and site obligations. Its interface contracts, reconfiguration-distance concept, evidence layer, world-model role, and readiness gates organize testable questions rather than establish validated performance. Their value depends on prospective cross-lot, cross-site, cross-scale, and cross-modality evaluation together with product-specific analytical, functional, stability, translational, and implementation evidence.

ACKNOWLEDGMENTS: None

CONFLICT OF INTEREST: None

FINANCIAL SUPPORT: None

ETHICS STATEMENT: None

REFERENCES

1. Tinafar A, Jaenes K, Pardee K. Synthetic biology goes cell-free. BMC Biol. 2019;17(1):64. doi:10.1186/s12915-019-0685-x
2. Silverman AD, Karim AS, Jewett MC. Cell-free gene expression: An expanded repertoire of applications. Nat Rev Genet. 2020;21(3):151-70. doi:10.1038/s41576-019-0186-3
3. Garenne D, Haines MC, Romantseva EF, Freemont P, Strychalski EA, Noireaux V. Cell-free gene expression. Nat Rev Methods Primers. 2021;1:49. doi:10.1038/s43586-021-00046-x
4. Crowell LE, Lu AE, Love KR, Stockdale A, Timmick SM, Wu D, et al. On-demand manufacturing of clinical-quality biopharmaceuticals. Nat Biotechnol. 2018;36(10):988-95. doi:10.1038/nbt.4262
5. Dahodwala H, Lee KH. The fickle CHO: A review of the causes, implications, and potential alleviation of the CHO cell line instability problem. Curr Opin Biotechnol. 2019;60:128-37. doi:10.1016/j.copbio.2019.01.011
6. Khanal O, Lenhoff AM. Developments and opportunities in continuous biopharmaceutical manufacturing. MAbs. 2021;13(1):1903664. doi:10.1080/19420862.2021.1903664
7. Adiga R, Al-Adhami M, Andar A, Borhani S, Brown S, Burgenson D, et al. Point-of-care production of therapeutic proteins of good-manufacturing-practice quality. Nat Biomed Eng. 2018;2(9):675-86. doi:10.1038/s41551-018-0259-1
8. Kightlinger W, Duncker KE, Ramesh A, Thames AH, Natarajan A, Stark JC, et al. A cell-free biosynthesis platform for modular construction of protein glycosylation pathways. Nat Commun. 2019;10(1):5404. doi:10.1038/s41467-019-12024-9
9. Stark JC, Jaroentomeechai T, Moeller TD, Hershewe JM, Warfel KF, Moricz BS, et al. On-demand biomanufacturing of protective conjugate vaccines. Sci Adv. 2021;7(6). doi:10.1126/sciadv.abe9444
10. Dopp JL, Tamiev DD, Reuel NF. Cell-free supplement mixtures: Elucidating the history and biochemical utility of additives used to support in vitro protein synthesis in E. coli extract. Biotechnol Adv. 2019;37(1):246-58. doi:10.1016/j.biotechadv.2018.12.006
11. Rasor BJ, Chirania P, Rybnicky GA, Giannone RJ, Engle NL, Tschaplinski TJ, et al. Mechanistic insights into cell-free gene expression through an integrated -omics analysis of extract-processing methods. ACS Synth Biol. 2023;12(2):405-18. doi:10.1021/acssynbio.2c00339
12. Olsen ML, Copeland CE, Sundberg CA, Aw R, Shaver ZM, Rao G, et al. Design-driven optimization of low-cost reagent formulations for reproducible and high-yielding cell-free gene expression. Nat Commun. 2026;17(1):3478. doi:10.1038/s41467-026-69605-8
13. Martin RW, Des Soye BJ, Kwon YC, Kay J, Davis RG, Thomas PM, et al. Cell-free protein synthesis from genomically recoded bacteria enables multisite incorporation of noncanonical amino acids. Nat Commun. 2018;9(1):1203. doi:10.1038/s41467-018-03469-5
14. Jaroentomeechai T, Stark JC, Natarajan A, Glasscock CJ, Yates LE, Hsu KJ, et al. Single-pot glycoprotein biosynthesis using a cell-free transcription–translation system enriched with glycosylation machinery. Nat Commun. 2018;9(1):2686. doi:10.1038/s41467-018-05110-x
15. Stech M, Nikolaeva O, Thoring L, Stöcklein WFM, Wüstenhagen DA, Hust M, et al. Cell-free synthesis of functional antibodies using a coupled in vitro transcription–translation system based on CHO cell lysates. Sci Rep. 2017;7(1):12030. doi:10.1038/s41598-017-12364-w

16. DeWinter MA, Thames AH, Guerrero L, Kightlinger W, Karim AS, Jewett MC. Point-of-care peptide hormone production enabled by cell-free protein synthesis. ACS Synth Biol. 2023;12(4):1216-26. doi:10.1021/acssynbio.2c00680
17. Borhani SG, Levine MZ, Gurramkonda C, Qu Y, Tao D, LeClair CA, et al. On-demand insulin manufacturing using cell-free systems with an "on-column" conversion approach. N Biotechnol. 2025;89:51-9. doi:10.1016/j.nbt.2025.06.002
18. Warfel KF, Williams A, Wong DA, Sobol SE, Desai P, Li J, et al. A low-cost, thermostable, cell-free protein synthesis platform for on-demand production of conjugate vaccines. ACS Synth Biol. 2023;12(1):95-107. doi:10.1021/acssynbio.2c00392
19. Murphy TW, Sheng J, Naler LB, Feng X, Lu C. On-chip manufacturing of synthetic proteins for point-of-care therapeutics. Microsyst Nanoeng. 2019;5:13. doi:10.1038/s41378-019-0051-8
20. da Silva SJR, Matthews Q, Cazaux S, Vigar JRJ, Santos BNR, Carvalho DCM, et al. International multisite implementation of distributed cell-free protein biomanufacturing to advance health and research equity. Sci Adv. 2026;12(22). doi:10.1126/sciadv.aeb7039
21. Cole SD, Beabout K, Turner KB, Smith ZK, Funk VL, Harbaugh SV, et al. Quantification of interlaboratory cell-free protein synthesis variability. ACS Synth Biol. 2019;8(9):2080-91. doi:10.1021/acssynbio.9b00178
22. Banks AM, Whitfield CJ, Brown SR, Fulton DA, Goodchild SA, Grant C, et al. Key reaction components affect the kinetics and performance robustness of cell-free protein synthesis reactions. Comput Struct Biotechnol J. 2022;20:218-29. doi:10.1016/j.csbj.2021.12.013
23. Dopp JL, Reuel NF. Process optimization for scalable E. coli extract preparation for cell-free protein synthesis. Biochem Eng J. 2018;138:21-8. doi:10.1016/j.bej.2018.06.021
24. Guzman-Chavez F, Arce A, Adhikari A, Vadhin S, Pedroza-Garcia JA, Gandini C, et al. Constructing cell-free expression systems for low-cost access. ACS Synth Biol. 2022;11(3):1114-28. doi:10.1021/acssynbio.1c00342
25. Borkowski O, Koch M, Zettor A, Pandi A, Batista AC, Soudier P, et al. Large scale active-learning-guided exploration for in vitro protein production optimization. Nat Commun. 2020;11(1):1872. doi:10.1038/s41467-020-15798-5
26. Zhu J, Meng Y, Gao W, Yang S, Zhu W, Ji X, et al. AI-driven high-throughput droplet screening of cell-free gene expression. Nat Commun. 2025;16(1):2720. doi:10.1038/s41467-025-58139-0
27. Hershewe JM, Warfel KF, Iyer SM, Peruzzi JA, Sullivan CJ, Roth EW, et al. Improving cell-free glycoprotein synthesis by characterizing and enriching native membrane vesicles. Nat Commun. 2021;12(1):2363. doi:10.1038/s41467-021-22329-3
28. Schwarz-Schilling M, Cohen I, Dupin A, Avidan N, Barak Y, Shimizu Y, et al. Autonomous biogenesis of all thirty proteins of the Escherichia coli translation machinery. Nat Commun. 2026;17(1):1028. doi:10.1038/s41467-025-67772-8